NDAORALCAPSULE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. Approved for parkinson's disease psychosis. First approved in 2018.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral small-molecule antipsychotic approved for Parkinson's Disease Psychosis, a rare neuropsychiatric complication affecting ~25-50% of PD patients. It works through inverse agonist and antagonist activity at serotonin 5-HT2A and 5-HT2C receptors, offering a mechanism distinct from traditional dopamine-blocking antipsychotics.
Peak12.8 years to LOE
NUPLAZID commands ~$596M in annual spending with zero direct competitors, positioning the brand team as steward of a rare-disease monopoly with stable growth and potential for team expansion into adjacent CNS indications.
Mechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications (1)
Career Relevance
NUPLAZID careers center on defending a rare-disease monopoly in a niche but growing therapeutic area; roles emphasize deep neurologist engagement, payer education on PDP prevalence, and pre-LOE strategy to extend market life. Working on this product means becoming an expert in an underrecognized but medically significant indication with lower patient volume but higher brand loyalty and pricing power compared to traditional CNS products.
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.